Sangamo Therapeutics is experiencing a 50% drop in premarket trading due to negative news from Pfizer.
Sangamo Therapeutics’ premarket value dropped by 50% due to a setback from Pfizer.
Sangamo Therapeutics’ premarket value dropped by 50% due to a setback from Pfizer.
Stay updated with the latests analysis and insights fromm etfsector.com
